DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

Phase 2

Completed

• Conditions: Head and Neck Neoplasms; Recurrence; Neoplasms, Second Primary

• Registration Number: NCT00400426
• Lead Sponsor: University of Aarhus

Brief Summary

Palliative radiotherapy for head and neck cancer is widely used but the effect and side effects are largely unknown. We will study the effect of short hypofractionated palliative radiotherapy (20 Gy in 4 fractions) on symptom intensity and -frequency as weel as side effects

Detailed Description

Not available

Study Timeline

• Study Start: 2006-11
• Study First Submitted: 2006-11-15
• Study First Submitted QC: 2006-11-15
• Study First Posted: 2006-11-16
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Status Verified: 2013-06
• Last Update Submitted: 2013-06-18
• Last Update Posted: 2013-06-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Incurable primary or second primary head and neck cancer
• Speaks and reads Danish
• Capable of filling out questionnaires for at leas two months after radiotherapy
• Age>=18 years
• Expected survival> 3months

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&N35 questionnaires and CTC AE 3.0 toxicity scores)	11 mths

Secondary Outcome Measures

Name	Time	Method
Survival	11 mths
Side effects	2 mths
Other treatments	11 mths

Trial Locations

Locations (1)

Department of Oncology; 🇩🇰 Aarhus, Denmark